

Bulletin from annual general meeting in Coala-Life Group AB (publ) on 30 May 2022

Coala-Life Group AB (publ) (the “Company” or “Coala-Life”) has held an annual general meeting on 30 May 2022. Below follows a summary of the decisions taken by the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the Company’s website www.coalalife.com).

The annual general meeting resolved:

- to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet for the previous financial year included in the annual report;
- that the Company’s accumulated results shall be carried forward in new account and that no dividend shall be paid for the previous financial year;
- to grant the board members and the managing director discharge from liability for the management of the previous financial year;
- that the board of directors shall consist of four ordinary members without deputy members and to re-elect Per Carendi (also re-elected as chairman), Ebba Fåhraeus and Peter Troija as board members and to elect Christian Jørgensen as new board member;
- that a registered accounting firm is to be elected as auditor and to new-elect Öhrlings PricewaterhouseCoopers AB as auditor;
- that fees payable to the board members until the end of the next annual general meeting shall amount to a total of SEK 1,000,000 out of which SEK 400,000 shall be paid to the chairman and SEK 200,000 to each of the other board members;
- that fees payable to the auditor is to be paid in accordance with approved invoices;
- to adopt the principles for the appointment of and instructions regarding a nomination committee;
- to repeal applicable guidelines for remuneration of senior executives;
- on an authorization for the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures by an amount and number corresponding to not more than 15 percent of the share capital and number of shares/votes in the company with or without deviation from the shareholders’ preferential rights; and
- to change the limits in the articles of association with respect to share capital and number of shares whereby the Company’s share capital shall be not less than SEK 18,750,000 and not more than SEK 75,000,000 and the number of shares in the Company shall be no less than 75,000,000 and no more than 300,000,000.

About us

Coala Life is a medical device company founded in Sweden focusing on cloud-based cardiac and pulmonary diagnostics. The company has developed and launched the Coala Heart Monitor - a multi-award winning, FDA-cleared and CE-approved product platform enabling long-term remote monitoring, analysis and algorithm-based diagnostics of heart and auscultation of lungs, remote in real-time. The Coala Heart Monitor is mainly marketed to healthcare providers as an Rx solution for use in patient's everyday life and home environment. The company's solutions are based on over 10 years of R&D, and are protected by more than 30 patents. The head office is based in Uppsala, Sweden and since 2019, the US office is based in Irvine, California. More than 10,000 patients have used, been diagnosed or are under long-term monitoring with the Coala Heart Monitor. In the Coala Care Portal, there are currently more than 1,700 doctors and nurses connected to more than 500 care providers. For more information see www.coalalife.com

For more information, contact:

Dan Pitulia, CEO Coala Life AB

+46 70 972 08 38, dan.pitulia@coalalife.com

Philip Siberg, Co-founder, Chief Strategy Officer and Head of IR

+46 70 790 67 34, philip.siberg@coalalife.com

Certified Adviser

The company's Certified Adviser is Erik Penser Bank AB.

Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm,

tel: +46 (0) 8-463 80 00

email: certifiedadviser@penser.se

Attachments

Bulletin from annual general meeting in Coala-Life Group AB (publ) on 30 May 2022